Jefferies raises Protherics price target to 140p

Protherics plc was maintained by Jefferies International Ltd. at a buy rating, but the price target was increased to 140p from 80p after the company announced a valuable £195 million deal with AstraZeneca for their CytoFab anti-sepsis treatment. But risks include a fuzzy timeline for the CytoFab phase 3 study and further delays in the Voraxaze filing and regulatory process. Shares of the London biopharmaceutical company were down 5.00p, or 6.17%, at 76.00p on volume of 1,587,902 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.